

Balazs Dome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1820734/publications.pdf>

Version: 2024-02-01

96
papers

3,549
citations

136950
32
h-index

155660
55
g-index

97
all docs

97
docs citations

97
times ranked

6071
citing authors

#	ARTICLE	IF	CITATIONS
1	Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program. <i>European Radiology</i> , 2022, 32, 4457-4467.	4.5	9
2	Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. <i>Journal of Pathology</i> , 2022, 257, 674-686.	4.5	26
3	Proteomic Workflows for High-Quality Quantitative Proteome and Post-Translational Modification Analysis of Clinically Relevant Samples from Formalin-Fixed Paraffin-Embedded Archives. <i>Journal of Proteome Research</i> , 2021, 20, 1027-1039.	3.7	20
4	The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation. <i>Translational Lung Cancer Research</i> , 2021, 10, 675-684.	2.8	3
5	EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. <i>Translational Lung Cancer Research</i> , 2021, 10, 662-674.	2.8	17
6	The landscape of small cell lung cancer metastases: Organ specificity and timing. <i>Thoracic Cancer</i> , 2021, 12, 914-923.	1.9	14
7	Molecular profiles of small cell lung cancer subtypes: Therapeutic implications. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 470-483.	4.4	64
8	Apelin promotes blood and lymph vessel formation and the growth of melanoma lung metastasis. <i>Scientific Reports</i> , 2021, 11, 5798.	3.3	13
9	Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. <i>Translational Lung Cancer Research</i> , 2021, 10, 1594-1607.	2.8	17
10	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. <i>Lancet Microbe</i> , The, 2021, 2, e300-e310.	7.3	60
11	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	10
12	Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor. <i>Pathology and Oncology Research</i> , 2021, 27, 1609926.	1.9	5
13	Clinical relevance of circulating activin A and follistatin in small cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 128-135.	2.0	3
14	3D histopathology of human tumours by fast clearing and ultramicroscopy. <i>Scientific Reports</i> , 2020, 10, 17619.	3.3	39
15	Longitudinal analysis of complete blood count parameters in advanced-stage lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 3193-3204.	1.9	3
16	Multicellular contractility contributes to the emergence of mesothelioma nodules. <i>Scientific Reports</i> , 2020, 10, 20114.	3.3	2
17	Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. <i>Clinical Cancer Research</i> , 2020, 26, 3819-3830.	7.0	23
18	Proteomic analysis enables distinction of early-versus advanced-stage lung adenocarcinomas. <i>Clinical and Translational Medicine</i> , 2020, 10, e106.	4.0	7

#	ARTICLE	IF	CITATIONS
19	Current therapy of KRAS-mutant lung cancer. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1159-1177.	5.9	66
20	Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. <i>Histopathology</i> , 2020, 77, 55-66.	2.9	13
21	HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. <i>Pathology and Oncology Research</i> , 2020, 26, 2523-2535.	1.9	15
22	Profiling the Protein Targets of Unmodified Bioactive Molecules with Drug Affinity Responsive Target Stability and Liquid Chromatography/Tandem Mass Spectrometry. <i>Proteomics</i> , 2020, 20, e1900325.	2.2	18
23	JAK-STAT inhibition impairs KRAS-driven lung adenocarcinoma progression. <i>International Journal of Cancer</i> , 2019, 145, 3376-3388.	5.1	54
24	Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. <i>EMBO Molecular Medicine</i> , 2019, 11, e9266.	6.9	72
25	KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. <i>Cancers</i> , 2019, 11, 1514.	3.7	19
26	Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC). <i>Translational Oncology</i> , 2019, 12, 1539-1548.	3.7	3
27	Expression of FGFR1 ⁴ in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity. <i>Cells</i> , 2019, 8, 1091.	4.1	10
28	A clonal expression biomarker associates with lung cancer mortality. <i>Nature Medicine</i> , 2019, 25, 1540-1548.	30.7	75
29	Lung Transplant Patients on Kilimanjaro. <i>Transplantation Proceedings</i> , 2019, 51, 1258-1262.	0.6	3
30	PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. <i>Clinical Lung Cancer</i> , 2019, 20, 363-369.e2.	2.6	28
31	Donation After Cardiac Death, a Possibility to Expand the Donor Pool: Review and the Hungarian Experience. <i>Transplantation Proceedings</i> , 2019, 51, 1276-1280.	0.6	2
32	Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. <i>Acta Oncologica</i> , 2019, 58, 1087-1094.	1.8	22
33	Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors. <i>Scientific Reports</i> , 2019, 9, 17359.	3.3	12
34	The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. <i>Journal of Molecular Medicine</i> , 2019, 97, 231-242.	3.9	29
35	Reshaping a multimode laser beam into a constructed Gaussian beam for generating a thin light sheet. <i>Journal of Biophotonics</i> , 2018, 11, e201700213.	2.3	3
36	DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients. <i>Journal of Pathology</i> , 2018, 245, 387-398.	4.5	23

#	ARTICLE	IF	CITATIONS
37	Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2018, 24, 3729-3740.	7.0	24
38	FGF2 and EGF induce epithelialâ€“mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. <i>Carcinogenesis</i> , 2018, 39, 534-545.	2.8	32
39	New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. <i>Lung Cancer</i> , 2018, 126, 139-148.	2.0	25
40	Role of (myo)fibroblasts in the development of vascular and connective tissue structure of the C38 colorectal cancer in mice. <i>Cancer Communications</i> , 2018, 38, 1-11.	9.2	5
41	Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. <i>BMC Cancer</i> , 2018, 18, 542.	2.6	16
42	Afatinib restrains K-RASâ€“driven lung tumorigenesis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	99
43	Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth <i>in vivo</i> . <i>Surgery</i> , 2017, 161, 735-746.	1.9	31
44	Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. <i>Journal of Surgical Oncology</i> , 2017, 116, 227-235.	1.7	19
45	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. <i>Molecular Cancer</i> , 2017, 16, 1.	19.2	196
46	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. <i>Neuro-Oncology</i> , 2017, 19, 1058-1067.	1.2	38
47	The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization. <i>Journal of Pathology</i> , 2017, 241, 441-447.	4.5	8
48	KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. <i>Scientific Reports</i> , 2017, 7, 39721.	3.3	62
49	Intrathoracic solitary fibrous tumor â€“ an international multicenter study on clinical outcome and novel circulating biomarkers. <i>Scientific Reports</i> , 2017, 7, 12557.	3.3	15
50	Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. <i>Scientific Reports</i> , 2017, 7, 16456.	3.3	12
51	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. <i>Journal of Pathology</i> , 2017, 241, 362-374.	4.5	162
52	Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. <i>Theranostics</i> , 2017, 7, 400-412.	10.0	71
53	BARD1 serum autoantibodies for the detection of lung cancer. <i>PLoS ONE</i> , 2017, 12, e0182356.	2.5	18
54	Inhibition of the transcriptional repressor complex Bcl-6/BCoR induces endothelial sprouting but does not promote tumor growth. <i>Oncotarget</i> , 2017, 8, 552-564.	1.8	13

#	ARTICLE	IF	CITATIONS
55	Lung transplantation in patients with incidental early stage lung cancerâ€”institutional experience of a high volume center. <i>Clinical Transplantation</i> , 2016, 30, 912-917.	1.6	11
56	Significance of Primary Tumor Location and Histology for Brain Metastasis Development and Peritumoral Brain Edema in Lung Cancer. <i>Oncology</i> , 2016, 91, 237-242.	1.9	10
57	Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2357-2369.	4.1	17
58	ÂÂLUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. <i>Journal of Experimental Medicine</i> , 2016, 213, 2671-2689.	8.5	79
59	Maternal bonding styles in smokers and non-smokers: a comparative study. <i>Annals of General Psychiatry</i> , 2016, 15, 32.	2.7	1
60	Mechanisms of vascularization in murine models of primary and metastatic tumor growth. <i>Chinese Journal of Cancer</i> , 2016, 35, 19.	4.9	23
61	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma â€” A multi-institutional study. <i>European Journal of Cancer</i> , 2016, 63, 64-73.	2.8	21
62	Differences in the Epidemiology of Rare EGFR Mutations in Different Populations. <i>Journal of Thoracic Oncology</i> , 2016, 11, e19-e20.	1.1	1
63	From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). <i>PLoS ONE</i> , 2016, 11, e0144797.	2.5	14
64	High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 13388-13399.	1.8	50
65	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 738-746.	1.1	70
66	Reply to Rare Versus Artifactual EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2015, 10, e80-e81.	1.1	1
67	Epigenetic downâ€”regulation of integrin Î±7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. <i>Journal of Pathology</i> , 2015, 237, 203-214.	4.5	28
68	Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. <i>PLoS ONE</i> , 2015, 10, e0117021.	2.5	19
69	A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. <i>PLoS ONE</i> , 2015, 10, e0123661.	2.5	19
70	The possible role of maternal bonding style and CHRNA2 gene polymorphisms in nicotine dependence and related depressive phenotype. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 59, 84-90.	4.8	4
71	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. <i>British Journal of Cancer</i> , 2015, 113, 963-969.	6.4	68
72	Mechanism of tumour vascularization in experimental lung metastases. <i>Journal of Pathology</i> , 2015, 235, 384-396.	4.5	53

#	ARTICLE	IF	CITATIONS
73	A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma. Memo - Magazine of European Medical Oncology, 2015, 8, 52-56.	0.5	0
74	Stromal Expression of Heat-Shock Protein 27 Is Associated with Worse Clinical Outcome in Patients with Colorectal Cancer Lung Metastases. PLoS ONE, 2015, 10, e0120724.	2.5	26
75	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. Oncotarget, 2015, 6, 394-408.	1.8	27
76	Massive Withdrawal Symptoms and Affective Vulnerability Are Associated with Variants of the CHRNA4 Gene in a Subgroup of Smokers. PLoS ONE, 2014, 9, e87141.	2.5	14
77	Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget, 2014, 5, 4426-4437.	1.8	81
78	Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 763-772.	5.6	59
79	Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). Lung Cancer, 2014, 86, 54-58.	2.0	3
80	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European Journal of Cancer, 2014, 50, 1819-1828.	2.8	68
81	Levels of plasma fibulin-3 and accuracy of identifying patients with malignant pleural mesothelioma.. Journal of Clinical Oncology, 2014, 32, e18543-e18543.	1.6	0
82	Cell migration or cytokinesis and proliferation? â€“ Revisiting the â€œego or growâ€•hypothesis in cancer cells in vitro. Experimental Cell Research, 2013, 319, 3094-3103.	2.6	84
83	Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma. PLoS ONE, 2013, 8, e77459.	2.5	17
84	A New Mechanism for Pillar Formation during Tumor-Induced Intussusceptive Angiogenesis: Inverse Sprouting. American Journal of Pathology, 2011, 179, 1573-1585.	3.8	59
85	Lack of Angiogenesis in Experimental Brain Metastases. Journal of Neuropathology and Experimental Neurology, 2011, 70, 979-991.	1.7	37
86	Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncology, 2011, 47, 487-496.	1.5	73
87	Lung cancer in never smokers. Future Oncology, 2011, 7, 1195-1211.	2.4	39
88	Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis. Journal of Thoracic Oncology, 2010, 5, 1120-1129.	1.1	110
89	Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Critical Reviews in Oncology/Hematology, 2009, 69, 108-124.	4.4	58
90	Development of Arterial Blood Supply in Experimental Liver Metastases. American Journal of Pathology, 2009, 175, 835-843.	3.8	39

#	ARTICLE	IF	CITATIONS
91	Recombinant Human Erythropoietin alpha Improves the Efficacy of Radiotherapy of a Human Tumor Xenograft, Affecting Tumor Cells and Microvessels. Strahlentherapie Und Onkologie, 2008, 184, 1-7.	2.0	28
92	Erythropoietin in Cancer: An Update. Current Molecular Medicine, 2008, 8, 481-491.	1.3	21
93	Alternative Vascularization Mechanisms in Cancer. American Journal of Pathology, 2007, 170, 1-15.	3.8	347
94	A Novel Concept of Glomeruloid Body Formation in Experimental Cerebral Metastases. Journal of Neuropathology and Experimental Neurology, 2003, 62, 655-661.	1.7	39
95	Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. Journal of Pathology, 2002, 197, 355-362.	4.5	109
96	Angiogenesis-dependent diseases and angiogenesis therapy. Pathology and Oncology Research, 2001, 7, 85-94.	1.9	74